AXL and C-MET serum levels in rectal cancer are significantly different from healthy subjects but did not correlate with tumor stage or survival during and after neoadjuvant/adjuvant therapy, while C-MET may hold promise for influencing future treatment responses. The gene discussed is AXL; the disease is neoplasm.